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Abstract  
Introduction: We want to present a rare case of Primary leiomyosarcoma of the thyroid (PLT) gland and review the 
literature on PLT including the differential diagnoses, pathology, and alternative treatment strategies.  
Presentation of Case: A 56-year-old man who underwent left side total thyroidectomy with diagnosis of substernal goiter. 
On pathologic examination, three different pathology clinics had a common opinion that this was a grade 3 pleomorphic 
sarcoma of thyroid itself. Positron Emission Tomography (PET/CT) obtained one month after surgery displayed no distant 
metastases. Loco regional radiotherapy (RT) to the thyroid bed was delivered up to a dose of 59.4 Gray (Gy) in 1.8 Gy daily 
fractions. PET/CT obtained three months after RT showed bilateral multiple lung metastases without loco regional 
recurrence. The patient received 6 courses of doxorubicin and cyclophosphamide based chemotherapy. A new PET/CT scan 
showed only two metabolically active metastases on both lungs. Because of disappearance of small metastases, the patient 
underwent sequential bilateral metastasectomy in one month interval. Pathology results verified the metastases of PLT. The 
patient is still alive without any signs of disease 6 years after RT and he is the only long surviving case reported up to now.  
Conclusion: The treatment protocols for PLT have not been well established yet, because of their rareness and poor 
prognosis. We believe that our case may be directive for PLT treatment. 
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Introduction 
Leiomyosarcoma constitutes %6 of head and neck tumours and they are exceedingly rare in thyroid 
gland (TG) itself [1]. It is believed that PLT originate from the smooth muscles of blood vessels in 
TG which has abundant vascularization. To the best our knowledge, there are only 21 
well-documented PLT cases in literature. This rare malignant nonepithelial tumour of the TG 
occurred in older patients with a median age of 65 years old [2, 3]. In our review of the literature 
we also found the same median age. In hematoxylin-eosin staining, the tumour is composed of 
characteristic spindle shaped cells with hyperchromatic, blunt-ended nuclei and abundant 
eosinophilic cytoplasm which are in disordered fascicular pattern [4]. The differential diagnosis 
includes primary versus metastatic sarcoma, medullary thyroid cancer and anaplastic thyroid cancer 
[4]. Immunohistochemical analysis is a gold standard for diagnosis. Although the primary treatment 
of PLT is surgical excision [1] adjuvant RT and chemotherapy should be considered in high grade 
tumours.   
Case presentation 
A 56-year-old male referred with a history of hoarseness, and sweating palpitation for three months. 
He also remarked the changing of his shirt neck size from medium to extra-large in this short 
period. He has been working in metal industry for 45 years. The medical history was unremarkable 
and no comorbidities existed. There was no history of radiation exposure. Physical examination 
revealed a diffuse enlargement of thyroid gland with no palpable cervical or supraclavicular lymph 
nodes. He was clinically euthyroid. Serum calcitonin, carcinoembryonic antigen (CEA), neuron 
specific enolase (NSE), thyroglobulin and thyroid hormone assay (thyroid stimulating hormone 
(TSH), serum triiodothyronine (T3) and thyroxine (T4)) results were within normal limits. 
Ultrasound (US) of the neck showed an ill-defined (7x4 cm) hypoechoic solid mass arising from 
the left thyroid lobe with no lymphadenopathy. Fine-needle aspiration (FNA) cytologies of the 
thyroid gland which was performed twice with US guidance were non diagnostic. Contrast 
computed tomography of the chest exposed a primary retrosternal multinodular goiter which was 
measured 7x4x5 cm. The mass with necrotic and cystic components encircled and displaced the 
trachea to the right and caused narrowing of its lumen by %30 (Figure 1). There was no pathologic 
mediastinal lymphadenopathy. Left lobe total thyroidectomy was performed without neck 
dissection. The patient was discharged on the third postoperative day without any complication. On 
gross examination, the necrotic and cystic components of the tumour were well circumscribed and 
the cut surface was yellowish and hemorrhagic. The gross tumour measurement was 11x7x5 cm 
(cranial-caudal, median-lateral and anterior-posterior). Histologically, there were well defined and 
encapsulated tumour cells which had no infiltration to the thyroid parenchyma and no invasion to 
the thyroid capsule. Vascular invasion was not present. In light microscopy the tumour cells 
showed a disordered fascicular growth pattern, elongated spindle or round cells with large vesicular 
nuclei and abundant eosinophilic cytoplasm. Immuno-histochemical staining of the slides with 
vimentin, desmin, alpha-1antitrypsin, creatine kinase (CK), thyroglobulin, myogenin, epithelial 
membrane antigen (EMA), CEA, Myo D1, thyroid transcription factor (TTF-1),  pancytokeratin, 
leukocyte common antigen (LCA),  smooth muscle actin (SMA), melanoma marker (HMB-45), S 
100 protein, cyclin d1, CD 68, CD 21, CD 23 and KI 67 protein was performed. The tumour was 
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strongly positive for vimentin, SMA, desmin, and negative for pancytokeratin and other epithelial 
markers except EMA. After excluding anaplastic, follicular, meduller, histiocytic and peripheral 
nerve tumours, three different pathology clinics had a common opinion that this was a grade 3 
pleomorphic leiomyosarcoma of thyroid gland itself. KI 67 score of the tumour was reported 
as %70. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1 Preoperative contrast CT revealed that the retrosternal mass encircled and displaced the trachea to 
the right 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Tumor cells surrounded by fibrous capsule are seen in the thyroid tissue. (H&E x100) 
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Figure 3 Desmin positive tumor cells (x200) 
 
PET/CT which was performed one month after surgery showed only one paratracheal lymph node 
with SUV:4.7 and no distant metastases. The lymph node was interpreted as a non-malignant 
enlargement by nuclear medicine specialist.  In multidisciplinary tumour board, it was decided 
that adjuvant loco regional RT had to be given immediately. After one and half months following 
the operation, first fraction of the conformal radiotherapy was applied to the surgical bed and upper 
mediastinal area. Irradiation was performed using linear accelerator 6 MV photon rays with four 
portals (anterior, posterior, right oblique and left oblique) and wedged based planning was used to 
get the best possible dose distribution inside the target volume with multileaf collimators. A dose of 
59.4 Gy to the %95 of the target volume was applied in 1.8 Gy daily fractions, 5 days a week for 
6.5 weeks. There was no grade 3 side effect necessitating interruption for RT schedule. PET/CT 
which was obtained three months after RT showed bilateral multiple lung metastases without 
locoregional recurrence. The medical oncology department suggested adjuvant therapy and patient 
received 6 courses of chemotherapy. Cyclophosphamide (2500 mg/m2) and doxorubicin (60 mg/m2) 
with mesna (2500 mg/m2) were administered intravenously (IV) over 2 hours on day 1 of a 21-day 
cycle. The patient tolerated this chemotherapy regime very well and no grade 3 toxicity was 
reported. A new PET/CT scan showed only two metabolically active metastases on both lungs (left 
lung inferior lobe median basal, 5.5 cm, standardized uptake value (SUV): max 12.25 and right 
lung superior lob 2 cm, SUV: max 3.2). Because of disappearance of small metastases, the patient 
was given a chance of two operations with wedge resections in one month interval. Pathology 
results verified the metastases of PLT. Low dose maintenance chemotherapy regime with 
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cyclophosphamide (50 mg/day/1-21days) and etoposide (50 mg/day/1-21days) were administered 
for one year. He was followed up in six months intervals by thorax and neck tomography thereafter. 
The only long term complication of therapies was the reactivation of the chronic active hepatitis B. 
He has been given lamivudine 1x1 for 2.5 years. The patient was still alive with complete remission 
6 years after RT. He is the longest surviving case reported up to now. 
Discussion 
Thyroid cancer represents less than %1 of all malignancies in the world, and most of the cases 
(%90 to %95) are classified as well-differentiated tumours arising from the follicular cells [4]. 
Primary smooth muscle tumours of TG (leiomyomas and leimyosarcomas) are rarely seen 
[5].Together with anaplastic carcinoma they are the most aggressive variant of the thyroid cancers 
with a very poor prognosis [5] PLT are more often reported in elder individuals and so far only 21 
well-documented cases have been reported in the world literature (Table1). Even though women are 
more prone to benign and malignant lesions of thyroid, PLT are equally seen in both gender [4].  
The etiology of PLT is not clear yet. Most of the reports in the literature show that cases are not 
associated with a benign or malign pre-existing thyroid lesion, and there is not any history of 
radiation exposure [6]. The PLT usually goes along with fast growing, painless masses and the 
symptoms of hoarseness and dysphagia [7, 8]. In thyroid isotope scanning, PLT can demonstrate a 
cold nodule or hyperplasia with increased and decreased uptake of radioactive iodine [1]. 
Ultrasound can reveal an ill-defined or well-defined hypo-echogenic mass with cystic or calcified 
components [1]. In most of the thyroid cancer, cross sectional imaging with contrast CT should not 
be used because it is associated with a delay in radioactive iodine treatment for up to 6 to 8 weeks. 
But these modalities can be very helpful to assess for local aggressiveness including extra capsular 
extension and invasion to the airway and esophagus. CT imaging of PLT in most of the thyroid 
cancer show a low-density mass with calcification and necrosis [1]. The tumor was commonly 
delineates an isointense mass on T1-weighted MR images and a mass effect of intermediate signal 
on T2-weighted images. After gadolinium injection, the lesion generally demonstrates a fair 
enhancement on T1-weighted images [9]. Fine needle aspiration cytology is the most important tool 
for diagnosis of thyroid diseases [5]. In PLT, it may show malignant spindle-shaped cells which 
directed someone to consider an unusual tumour of the thyroid [4]. 
The main differential diagnosis includes anaplastic thyroid carcinomas (ATC), solitary fibrous 
tumours, spindle cell tumours with thymus-like differentiation, medullary carcinoma and other 
sarcomas [1]. PLT usually displays smooth muscle cells with histological features characterized by 
atypical pleomorphism, prominent mitotic activity, necrosis, hemorrhage, and invasive and/or extra 
thyroidal growth [4]. Leiomyosarcoma is extremely rare in the TG itself. Diagnosis should be 
clarified by immunohistochemical staining methods when there is a tumour resembling spindle 
shaped malignant cells [2]. Intermediate filaments are useful markers for diagnosis. The 
cytokeratins, which are specific of epithelia, are the largest and most diverse class of intermediate 
filaments. Vimentin is another important intermediate filament protein that is expressed in 
mesenchymal cells [7]. Carcinoma of the TG usually express both of these markers [7] and 
anaplastic thyroid carcinoma sometimes stained with vimentin. Desmin is another good marker of 
muscle origin and carcinoma of the epithelial tumors generally do not express it except lung tumors. 
In our case, diffuse and strong staining with desmin and vimentin and no reactivity to the Pan CK 
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were revealed by three different pathology clinics. Anaplastic thyroid carcinoma mimics PLT 
structurally and functionally and spindle cells of anaplastic thyroid carcinomas generally express 
Pan CK and vimentin but do not desmin. On the other hand, thyroglobulin, calcitonin, protein S100 
and chromogranin are never expressed in PLT [1].  
Medullary carcinoma can show variable microscopic features including spindle cells. However, 
differential diagnosis is easy because tumour cells are positive for chromogranine A, 
synaptophysine, ACE and calcitonin [1]. Other spindle characteristic, solitary fibrous tumours are 
usually positive for CD34, BCL2, CD99 and vimentin [1]. 
Metastatic malign tumours of the thyroid are infrequent [8, 10]. Autopsy series of the patients 
who died from cancer revealed %2-24 of thyroid metastasis. Lam and Lo have reported 79 patients 
with metastatic thyroid tumours in 1998 [8]. The most common sites of the primary tumour are the 
kidneys, stomach, lungs, mammary glands, ovaries, colon and melanomas respectively [8, 10]. The 
clinical presentations of the metastatic thyroid tumour may be similar to those of primary thyroid 
tumour, including enlargement of the neck, hoarseness and dysphagia [8]. The presence of known 
tumor history, clinical examination and imaging studies will assist to diagnosis. 
Some authors believed that benign leiomyoma has differentiated leimyosarcoma. Leiomyoma of 
the thyroid is an extremely rare benign tumour and malignant transformation to another extremely 
rare leiomyosarcoma is not eventual [2]. Thyroid anaplastic carcinomas can accompany with 
sarcoma like features (spindle cell) [5] and spindle cell sarcomas arise de novo as a component of 
anaplastic carcinoma [1]. Chetty et al. have postulated that such smooth muscle differentiation may 
thus arise as a result of metaplastic modification or by de-differentiation and re-differentiation of 
anaplastic thyroid carcinoma [11]. 
Another aspect for the origin of PLT puts forward that it may originate from the smooth muscle 
component of organ capsule or vascular walls [2]. Adachi et al. in their first report of the autopsy 
case of PLT stated that PLT originated in the vascular walls, and supported their idea with the 
evidence that there was no smooth muscle in the thyroglossal tract [2]. Kawahara et al. agreed with 
this opinion. They also reported the immunohistochemical findings of the PLT for the first time [2]. 
Thomas and Fine’s report supported the idea that leiomyosarcomas might originate in the vascular 
walls of TG [2]. However it is very difficult to establish precisely whether PLT is originating from 
the smooth muscles of the TG or from another adjacent muscle organ because in the most cases 
tumours are in advanced stages at the time of diagnosis.  
Consequently, these tumours originate in the tissue elements within the thyroid gland and show 
invasive growth within the thyroid parenchyma. The tumour often invades into the surrounding 
thyroid parenchyma and the adjacent structures rather than metastasis to the regional lymph nodes 
[1, 2]. Despite different and aggressive treatment modalities most patients have got metastatic 
diseases (lungs, liver, myocardium, kidney, pancreas, small bowel, colon, peritoneum, brain and 
bones) and die because of metastatic diseases. There is not any specific standard treatment in PLT. 
Initial treatment generally begins with surgical excision. In high grade patients, 3 different adjuvant 
chemotherapy regimens take place in literature. The median survival of the metastatic patients who 
received RT- chemotherapy was 8.5 months (range, 6-11), as compared with 5 months (range, 1-51) 
for the patients who did not receive these therapy modalities. 
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Conclusion 
The treatment protocols for PLT have not been well established yet, because of their rareness and 
poor prognosis. We believe that aggressive therapeutic approach is necessary for aggressive cancers. 
Our case may be directive for PLT treatment. 
Consent 
Written informed consent was obtained from the patient himself for the publication of this case 
report and any accompanying images.  
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Table 1 Clinical data on 20 reported cases of leiomyosarcoma and on the current case1,3,4,12,13,14,15,16 
 
Case Reference Age 
(y) 
Location Gender Presentation Size 
(cm) 
Operation TFT Adjuvant 
Chemotherapy 
Metastatic Disease Outcome 
1 Thompson 
et al.12 
64 Right 
Lobe 
F Mass   
multiple 
nodules 
7.5 Excision 
(rezidü+) 
- - Post op lung met 
(2 months); 
 liver-pleural- 
peritoneal met 
DWD, 5 
mo 
2  
Thompson 
et al. 
45 Left Lobe M Enlarging 
mass for 4 
weeks; 
weight loss 
(13.5 kg) 
9  ST - Doxorubicin Lung met  Alive, 11 
mo 
3 Thompson 
et al. 
68 Left Lobe M Mass; 
hoarseness 
1.9 - - - Lung met  DWD, 18 
mo 
4 Thompson 
et al. 
83 Sub 
Sternal 
M Enlarging 
mass; 
dysphagia 
5.5 Excision - - Lung met DWD, 3 
mo 
5 Kawahara 
et al. 12 
 
82 Right 
Lobe 
M Mass; 
hoarseness 
5.5  ST + 
BLND 
N - Submandibular  
recurrence 
DWD, 4 
mo 
6 Chetty et 
al.12 
54  F No 
symptoms 
3.5 ST N - - Alive,15
mo  
NED 
7 Just et.al. 12 
 
83 Left Lobe F Mass, left 
arm pain 
5.7 ST N - Vertebral met DWD, 2 
mo 
 
8 Ozaki et 58 Left Lobe F Mass 5  TT +  - - Alive,24 
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al.12 central 
LND 
mo NED 
9 Ege et al.4 
 
56 Left Lobe M Enlarging 
mass; 
dysphagia; 
hoarseness 
2.7  TT 
+ 
central 
LND 
N - Pulmonary met 
(post op 8 mo) 
DWD, 8 
mo 
10 Mansourı 
et al.3 
63 Right 
Lobe 
F Mass; 
hoarseness 
7 TT N - lung met  
(post op 2 mo)  
bone-liver-peritoneal 
met 
(post op 5 mo)  
DWD, 5 
mo 
11 Amal et 
al.1 
 
72 Left Lobe F Mass of the 
skin fistula 
5  ST N -   
12 Wang et 
al.13 
65 Right 
Lobe 
F Enlarging 
Mass; weight 
loss 
8 TT + 
BLND+  
thymectom
y 
 Ifosfamide + 
Doxorubicin  
 - 
13 Kaur et 
al.12 
? ? ?     - Nodal met  Alive, 12 
mo 
14 Takayama 
et al. 12 
66 Left Lobe F Enlarging 
mass 
8.5 ST N - Lung met Alive, 3 
mo 
15 Tanboon et 
al. 14 
 
64  F   TT  - Lung + liver met  DWD, 3 
mo 
16 Day et al.15 
 
43 Left Lobe M Mass; 
hoarseness 
1.8  N Imatinib Lung met DWD, 6  
mo 
17 Hiroko et 86 Left Lobe F     -   
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al. 16 
18 Tulbah et 
al.12 
6  M Upper 
respiratory 
tract 
infections 
5 ST  - ? DWD, 4  
mo 
19 Tsugawa et 
al.12 
90  F Mass 8 ST  -  DWD, 2 
mo, 
pneumoni
a  
20 Adachi et 
al.12 
74  F Pain; 
dysphagia 
weight loss 
12   +  DWD, 1 
mo 
21 Lida et al.12 72 Right 
Lobe 
F Mass 3  ST + 
BLND 
 - - DWD, 51 
mo 
22 Current 
Case 
56 Left Lobe M Hoarseness; 
enlarging 
neck 
circumferenc
es 
11 ST N Cyclophospha
mide + 
doxorubicin 
with mesna; 
maintenance 
with 
cyclophospha
mide +  
etoposide 
Bilateral Lung 
metastasis 
Alive, 61 
mo, NED 
 
F, female; M, male; TT, total thyroidectomy; ST, subtotal thyroidectomy; BLND, bilateral lymph node dissection; LND, lymph node dissection; TFT, thyroid 
function test; N, normal; DWD, died with disease; met, metastasis; NED, no evidence of disease. 
 
